However, spironolactone is associated with serious adverse events, including hyperkalemia and gynecomastia. [10,11] Consequently, clinical benefits related to the use of spironolactone are ...

The analysis results suggest that the use of spironolactone is associated with an incidence of adverse events, which may have an impact on treatment compliance. JL and CB designed the study ...

The US Food and Drug Administration has approved the use of finerenone (Kerendia) in heart failure (HF) patients with mildly ...

Doctors are regularly overlooking a common hormone-driven cause of high blood pressure -- primary aldosteronism -- ...

Just like any other profession, even healthcare professionals can often make mistakes like missing symptoms or misdiagnosing ...

In this study, scientists wanted to understand exactly how spironolactone protects the kidneys. They discovered that the drug helps maintain a special layer in the kidneys called the glycocalyx. This ...

Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

Patients with heart failure and atrial fibrillation (AF) at the time of mitral transcatheter edge-to-edge repair (M-TEER) for ...

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

The study revealed that people with these genetic changes were found to be more than twice as likely to develop heart failure ...

The FDA has approved Kerendia® (finerenone) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits.

Research shows heart attack deaths have plummeted by nearly 90% since 1970, while deaths from heart failure and arrhythmias have increased, highlighting new cardiovascular challenges.